Q1 2020 Earnings Call
<unk> cannot Doris Chief Financial Officer Amneal. Please go ahead.
Good morning, everyone.
This morning, we issued a press release reporting quarterly results.
The press release as well as the slides on this call are available on our website at www Dot ml Dot com.
Conducting a live webcast will be scope and the replay will be will be available than not website. After its conclusion.
Please note that today's call is copyrighted material about meal and I'd be really brought rebroadcast without the companys expressed written consent.
To remind you that statements made during this call, stating managements outlook or predictions for future periods forward looking statements.
Mr based solely on information that is now available to us.
We encourage you to review the section entitled.
What's you know restatements. Some forward looking statements you know earnings release and presentation, which applies to be school.
Our future performance made different due to numerous factors many of which are listed on our most recent annual report on form 10-K, and our revised and updated quarterly reports on form 10-Q current reports on form 8-K, which you can also find in our website RMBS. It sees website, that's you see that.
[music].
We also discuss certain non-GAAP measures you will find important information I don't know your somebody's Mezz, Georgia, and reconciliations to U.S. GAAP earnings release.
Included in the appendix of today's presentation, you will find U.S. GAAP financial statements that correspond to some of our non U.S. GAAP measures.
Our first throughout the presentation.
On the call. This morning, Horseshoe propel intend to Patel, our co CEO.
In addition, Andy Boyle, our executive Vice President of commercial operations.
At this school senior Vice President of specialty commercial and Steve Manzano, Our general counsel in corporate Secretary I don't know line it will be available for the Q and they session.
I would like to note that's all about sort of different locations do you do called 19. So please bear with us if there any technical issues.
And with that I'd like to turn the call over to Shira.
Thank you think your Dsos and good morning, everyone does so as join a meal as a CFO in March and we are pleased to have them on our team.
I'll begin by addressing them in response to covert 90, plus I want to acknowledge the difficult in warm and we had all navigating.
As individuals as a company and you know what communities around the world.
Well, it's hard to go out to those impacted by this global endemic and we hope, although if you are healthy and safe.
We are deeply proud of how m., Neil has and continue to respond to the cold with 19 cases.
You bet proactive and Mobileyes quickly to you all the wood business to protect the Hell talk what would colleagues and communities while sustaining the supply of medicines for patients.
Yes stop at least a strategic task force made about top leaders across all business functions to ensure that would put it back and there's always see a response and enabling mitigation and continued de crossed over business operations I.
I want to recognize the exceptional that puts up or what employees.
Operational teams have kept doing facilities are running to ensure the wood products get across the finish line.
We have also ramped up production in certain areas to help meet new demand or distribution teams have done a terrific job getting older products outdoor customers. In addition, we're selling and marketing teams have had been you know they do and productive do as they work remotely for example, they have created.
New procedures and automated processes to deliver samples to physicians and launched what's your lunch and learns to continue physician engagement.
Importantly, we supply chain also continued to perform well Oh procurement teams have done a great job of sourcing and assuming that do pharmaceutical ingredients needed to keep on manufacturing in production operations running as smoothly as possible as we continue strengthening your supply chain.
We're pleased with how we operated during the quarter and confident in our ability to continue procuring materials and delivering finished products.
Given the nature of our business and I mean, its commitment to patient access we believe it is over responsibility to to help combat the global code 90 pandemic.
Quickly exit a production of hydroxy chloroquins, so quick to move beyond our traditional fortress and market share, which helped us meet demand from states and government agencies and continue supplying this medication to lupus NRT patients.
While we have seen some disruptions as a result of this find them it.
Our teams have done an incredible job minimizing the impact to patients customers and I'm deal.
With that we're diversified supply chain substantially U.S. manufacturing footprint and track record of quality, we had in <unk>, we had welding position 40 unique challenges of covert 19.
I'd say this could ice is a shining a spotlight on the dependency on the American form what should we go supply chain on foreign manufacturing. The U.S. is almost completely reliant on other countries supply chains and manufacturing for the production of <unk> and key starting materials to produce.
Finished drugs.
It is more to better than ever.
The need for more drug manufacturing to be in the United States, we want to ensure that grain another global emergency comes along.
We are ready and able to ramp up production and manufacture lifesaving medicines.
No there is a bipartisan support around this issue and people on both sides of wild understand its importance.
For National Security.
As the largest U.S. decides generic drug manufacturer, we believe M. Neal is uniquely positioned to be a key part of the solution. We look forward to participating in the end the dialogue.
Now let me review the first quarter, we're pleased with our operational and financial performance, which demonstrates continued progress in or whatever it's to bid and nearly two point, though.
We had focused as ever on improving or what operational execution by sending their supply chain and could easing plant utilization, reducing cost and addressing inefficiencies. All of this is expanding your margins. We also continued to execute against this strategic priorities, we laid out last quarter.
These include revitalizing go wherever generic business growing go a specialty franchise and diversifying the business intelligently. We remain focused on these initiatives even as we navigate the challenges created by call. It 90.
And I believe.
We will continue building over the momentum in 2020 and beyond.
Let me now provide an update on our business segments generics that is solid start to the yet.
Notably achieved 42% adjusted gross margin during the quarter, which is a head over a long term goal of 40%.
We have two main priorities in this business strengthen the base business entirely new product launches with enhanced preparedness and execution.
Continued building on our large portfolio products and remain on track in terms of new product launches. We are growing go with market share as we continue shifting our focus to developing and commercializing more complex high value products last August we set out to launch at least.
In high value genetics products by August 2021.
And we have already launched five including most recently genetic mutation status during most system.
Our duty senseless to market launches, so Jay equation, so no wedding and kind of break that up and running and we are pleased with the results to date.
Sure there will provide more details on or what R&D pipeline and what real coming up in genetics.
In specialty we are continuing to grow and franchise, we outperform expectations on almost all over products. During the first quarter looking at some highlights I do you saw year over year revenue and Trx growth of approximately 31% in 17% respectively. They went.
By continued traction in our marketing initiatives units ordered revenues and description also increase year over year by 33% an 18% respectively. This reflects continued success also exists existing marketing programs and favorable comparison to prior year period.
Through the weekend. It May force, we have seen a minimal negative impact from coal with 19 on all major specialty products prescription refills have remained strong while new patient starts have dipped slightly postcode 19, we expect new patient starts to do soon.
No growth at the same break we experienced in the first quarter.
Turning now to or what efforts to diversify the business into intelligently through new distribution channels.
We completed or what acquisition of the majority stake and I'd get on January 31st as planned. It is operating as an independent subsidiary and we have essentially completed the integration.
With this differentiated platform.
We are identifying new opportunities to buy do so government agencies and it was strategy of selling more unit dose products, which is a nation business continues to be a part of who started as you put I've got I've got platform.
We will continue to evaluate opportunities for value, creating partnerships and smart accretive M&A transactions, we believe there will be exciting.
Inorganic growth opportunities as a result of recent dislocation in the market.
And the remains a puts you in as Dick and disciplined.
Which we believe positions us for continued growth.
<unk> through new distribution channels, new geographies or complementary addition, Stewart specialty business.
As we look ahead to the rest of the year. There's no question Koby 19 has added complexity and a degree of uncertainty doing business and I would industry. Overall for example in the second quarter, social distancing and the reduction in physician visits and elective surgeries main bike wall.
In terms of certain products across both specialty Enginetics importantly, however, we have a diverse business and our solid first quarter results demonstrate that our strategy to revitalize. This business is working we're confident that the strength and resilience of our team and I would.
Focus on execution will enable us to achieve lowered operating and financial goals with that I'll now turn the call or did you can do.
Good morning, everyone Bankers York I would also like to acknowledge tremendous effort. So 14 during the cold reigniting brain damage. We have begun a number of actions to help mitigate the impact on the crisis on our company and stakeholder then too little white support to the industry and go to them.
Hi, Brad we can do include strengthening or would own supply chain and working closely with Brad drill and locally didn't think to award short did you have with venture for drugs and our core we have always been a mission driven organization and our culture of making how did the bought the boat.
Never been more important than today.
As you can see from over twice, what the rebuilds or focus on operational excellence you'd batting who we have strengthened our supply chain and improve the brought this is that it's done by reach or wood products come to market. We have managed to invent dirty more efficiently and worked with customers.
Supplier to manage wallboard got while these efforts are not done we are proud off what broadridge to date and went generic business. It's fighting on all the named ours and we have seen where these strong results in both our base business at a recent launches we have worked aggressively to exit.
And then in the base business wed be able to approximately 250 products. Currently marketed we continued to workloads, maybe there were customers and analyze opportunities to grow market share.
And the same time really being hyper focused on new launches or the last month, we have launched 16 products, including multi point I read a new complex genetic. These afterwards that was substantially improved our gross margin.
Finally, as the current crises that demonstrated.
How's manufacturing and quality infrastructure are more important than ever or what ability to develop and manufactured product in how well they shouldn't Oh, it's too big and one day job Jane do in the market ready swiftly.
And then he though in the last few months, we have been you, but do address numerous product short did you, resulting from the pandemic on Dod NB front or genetics by Black is progressing nicely earlier. This year, we find that were forced inhalation product, which is the drug device combination will be.
Broke yard exclude the west to fly instead, that's for these broader entities just than they did example offer what commitment to dialup procure regulatory approval and launch complex high value products.
Hi, Brad, Yes to entry and all put more directly maam you.
Moreover, we are on track to meet their work I get bilingual Randy to Brent be byproducts in Brentwood brand B and many of these are potential wants to market a fortune or do we currently have 95 products in the pipeline are waiting at the approval and approximately 94 products in development.
Oh, what I really do Dialup, many new and high value brought it reflects that strand, and but I talk about what I Didnt do organization, our de centralized R&D model allows us to big I'd run Big dog dosage form specialization and create more deep well then theres an excellent across the globe.
For instance, or what's driving injectable focused R&D and manufacturing bank. There has already successfully developed and launched multiple products since the inception, a few years ago and that means that we have a growing injectable business that gives them access to attractive institutional and hospital.
These end markets importantly, we are actively working to increase over the injected boats manufacturing capacity in both the U.S. and India as Bart outboard longer term growth plans to become a key player in the U.S. market. We expect these will be significant growth driver.
Over the coming years finally, we continue to evaluate the board you're gonna be stir you'd be like what R&D and regulatory crush structure, what's the opportunity outside the U.S. why equal we'd 19 has been factored goes airports do an extended quarter brought this up expanding geographically.
Then it starts with <unk>.
As a reminder, last year, we entered into a partnership with also reach will help us grow at international presence, we expect to find or whats plus product in the coming we coming weeks with more to Paulo.
I will touch on our specialty business, which continues to grow substantially and ratably, we couldn't be any do I look at mortified Mort off or what R&D budget. We are focused on the strategic selection of products and leveraging our strong infrastructure as well as opportunities to selectively enlighten.
Products from external partners and acquired businesses that would be good evening hours and makes strategic sense.
One off or keep biplane ethic is the IBX two or three development program, though we have slowed patient enrollment in our phase three study in response to Korea 19, we still expect topline data in the second hop up 2021, we remain excited about this brought its potential and.
Expect commercialization in Brentwood run degree as we announced last quarter, our agreement with Koshi Biodefense. He has expanded our CNS pipeline into neuromuscular disorder. We now have the exclusive rights to the new drug application and commercialization of gave one boost Baron board there.
We went off my thing Youre gravity reach we expect to flying by the fourth quarter, Brent Btwenty one.
With respect to by the new doors, we added one thing he can do they were pipeline Biosimilar version sub neupogen, neulasta and lasting and not actively working to add additional products. This is an exciting area for growth and we are pushing more work to become one of the key biosimilar player.
The United States market. Our goal is to look at capital towards mid and late stage assets through partnerships and not to spend significant on early stage development and manufacturing risk in somebody really mean passionate about our specialty business and look forward to leverage.
And your work commercial operation as we continued to grow I want to again, thanks, our dedicated employees for everything they have done to support our business as we work to confront the crises.
I also think of what customers and suppliers for their continued partnership.
We are all soldiers in the thing by together as a company and industry and as a matter you couldn't we are going to overcome the pandemic now let me turn the call over $2 close to discuss our financial results for the quarter I suppose.
Thank you can do.
Let me just straight into the results from a top line perspective net revenue the first quarter Twentytwenty was 499 million up.
<unk> percent compared to Q1, 2019 and up 25% sequentially.
This growth was driven by the acquisition about care and the growth of new generic products and specialty brands, which offset generic competition and the sale of our international business last year.
<unk> sales were not in many factor in the quarter must be mostly the navy their production.
Our net revenue was slightly ahead of our expectations, mostly a top gear and it reflects strong execution by our commercial and supply chain teams in making substantial volatility of customer needs.
Wholesaler inventory levels for our products what at normal levels at the end of Q1, Twentytwenty, but there may have been some early you also prescriptions due to customer supply concerns with Colby 19.
Adjusted gross profit of 225 million was up 5% compared to Q1, 2019, and 30% sequentially driven by the topline growth.
The first quarter Twentytwenty margin of 45% was down from Q1, when do you 19.
Hi are perfect the ability of our new products and higher manufacturing absorption rates, partially offset price erosion and be inclusion Obama care, who has a lower margin profile.
The sequential margin expansion reflects favorable product mix, partially offset by the addition of <unk>.
Moving on to operating expenses.
Our in do 35 million and this DNA of 69 million declined in the first quarter due to our efforts to reduce unproductive activities.
Walker sort of R&D spend.
R&D expense was slightly lower due to cope with 19 disruption and timing of projects and has been geared more towards the latter part of the year.
Adjusted EBITDA 134 million eased up from 112 million in Q1, 2019, and the 81 million of the fourth quarter last year.
This growth reflects the positive revenue trajectory.
Our focus in operating expenses and not care, which contributed 7 million into quarter.
Adjusted diluted EPS of 20 cents used up substantially from Q1, Q4, 2019, well, we delivered 14 cents an eight cents respectively.
Finally, we're pleased with our operating cost no 49 million, it's substantial improvement to prior periods.
It's reflects favorable comparisons to Q1 2019, along with top line growth and lower restructuring and integration expenses.
In summary.
It was a very good starts will be year, reflecting our sound strategy and solid execution.
Let me now moved to our segment results starting with generics will net revenue of 353 million was down 30 million from Q1 2019.
But up 53 million sequentially.
The prior year decline primarily reflects the dynamics.
First.
29 million reduction you did the divestment of our international operations and shifting of oxymorphone, the specialty segment last year.
Second sales increased from the lots of generic Barry Jonas of no marine and Carafate, which offset lower sales.
Liberal fire oxide sodium and.
And that go up and I know you do competition that emeritus late last year.
Adjusted gross margin of 42.1% was stable relative to Q1 of 2019 and substantially ahead of Q4.
The growth compared to Q4 last year was driven by new product launches.
Our manufacturing absorption and operational efficiencies.
So we have discussed we're targeting 40% plus long term growth long term gross margin for the generic business and while were pleased with the first quarter, there's more to be down before we achieved 40% plus in a sustainable way.
Finally, adjusted operating income of 303 million reflects our topline growth favorable product mix.
Just investments in some favorable expense timing.
Let me now turning to our specialty segment with net revenue of 88 million into quarter up 38% compared to Q1 2019.
Adjusting for the classification of Oxymorphone net revenues grew 14% driven by right three units.
This performance reflects the ability of our sales and marketing teams to stay productive while working remotely and shipped activities, such a sampling and training to virtual basis.
The decline from the prior quarter was expected and reflects seasonal factors.
Adjusted gross margin of 74.6% was inline with our expectations and the unfavorable variance to prior year was driven by the reclassification of oxymorphone, which has a lower margin profile.
Finally, operating income of 39 million reflects topline growth.
It's been up expenses and seasonality compared to prior quarter.
Let me not moving to off care.
58 million in net revenue in the quarter.
This new segment only reflects third party product sales, which account for approximately 80% of Bob you're still adult cells.
Yeah milk products sold via this channel are reported in the generics segment consistent with prior years.
As you May recall, we close this acquisition on January 31st.
Well. This period includes just two months of sales we believe the business benefited by strong demand by the department of defense into V. Eight to build inventory in anticipation of Kobin 19 supply challenges.
Let me now turning to our cash flow balance sheet and also discuss two discrete events in the quarter.
First as you can see Wendy Q1, 407 million up costs.
This reflects solid operational performance and temporarily borrowing 300 million from our 500 million ABL facility.
It's temporary ballroom.
It was driven by an abundant abundance of caution us koby 19 live to substantial disruption in the financial markets.
As markets improve quick turn 200 million and expect to return the remaining 100 million into next few months provided markets continue to function properly.
The second discreet event relates to at $110 million cost tax refund, we expect to received in the second half of 20 to 20.
This is driven by new legislation and IRS guidance, which allows companies to carry box net operating losses to offset.
Taxable income in taxes paid over the last five years.
Secondly, we plan to utilized approximately 330 million of existing net operating losses in support of these stocks verifone.
Let's see doing the discrete nature of this event, we have taken to put then step to exclude it from already operating cash flow guidance.
Moving onto our balance it.
Did you can see we have subs, we have substantial financial liquidity in excess of 600 million and no near term debt maturities.
Thank you.
<unk> strong financial performance in smart use of cost will provide and not your old reduction of leverage over time.
Looking ahead, we remain comfortable with the financial guidance, we provided in February and he may be helpful to provide some insight.
First we have a broad generic product portfolio that is not overly concentrated in one or two products.
And our robust supply chain.
Having said that we have a showroom slow down in the second quarter. That's patients may postpone preventive care or health care visits do you do coffee 19.
Second.
We're not overly reliant pharmaceuticals administered within hospitals, you know commercial team slumped to be opportunistic in pursuing new business and leverage new product introductions.
Sure.
Your provides a stable platform for growth with long term top looks in good visibility.
Okay. This business not typically five years, if we can increase volumes over time.
Finally, we continue to be focused on improving our efficiency in operating expenses.
With that let me turn to phone over to Shira.
Thank you torsos before we open the floor to Q anyway, I wanted to emphasize that in Riyadh relentlessly focused on reinvigorating the complete and building up nearly two point, though despite the added complexity and uncertainty created by calling 19, we delivered a strong quarter.
And thanks to the hard work and resiliency Ofourteen.
We are positioned to achieve our goals and to drive growth in 2020 and beyond Thank you with that I'll turn the call to the operator to open it up for questions.
We will now begin the question answer session chassis question. You Me Press Star then one on your Touchtone phone, if you're using any speakerphone. Please pick up your handset before person the keys to withdraw your question. Please press Star then too please limit yourself to one question and one follow up if you have any further questions you may reentered the.
Question Q.
At this time, we'll pause momentarily to similar roster.
Our first question comes from Greg Gilbert from Suntrust. Please go ahead.
Hi, Good morning, guys and welcome Tostitos I wanted to start with you truck on your comments about a U.S. centric.
Supply chain that how feasible and practical is it to have a more U.S. centric supply chain and what do you plan to do as a company to make that happen I'm in a bigger way then you already have and my follow up will be for tend to since you brought up the first to file opportunity is there anything more you can say about that and held product, presumably you filed and we're now.
Not sued.
Can you give us any more color about that thank you.
Thank you, Greg and a good morning.
The U.S. centric supply chain look it took years to get to this level disposition, where.
Supply chain is highly line and that other reasons and you guys know the history for lost 50 years hobby mood or sees antibiotics in China, Oh, the concentrated that and then a lot of finished goods production in India than you'd go up and U.S. we have.
No.
Not much of a apiay manufacturing.
It is a long term.
Event, it is not going to happen overnight, but.
What we are hearing from them from the Congress and administration is that they do want to bring back.
Certain essential medicines, such as and not maybe 100% capacity, obviously, but let's say 30, 40%, 50% so weekend in.
Okay. So the emergency ramp up the production and we're not completely aligned on ER on floating sources. So.
The essential drug list would be probably we don't know how big that couldn't be 50 products hundred products.
They it would have to have incentives for the manufacturers to invest into United States supply chain.
And.
Those cannot be temporary it has to be long term a permanent changes.
We as Emil well positioned because we already have a large production facilities here, we do not I may be I facility, we do SVP I facilities in India, and we would build those whether it is an infant mendacious side or on a small molecule Oh I gave it will it said.
Project that would have to start with the support of Congress and then it will continue on for three years surgeon production then after that five years seven years 10 years, but.
We believe that in that timeframe, we can bring back up a certain capacity and capabilities as well because we need to a train the people and bring the skill sets here as well.
Jim do you want to answer that yet.
Sure Hi, Greg Good morning.
As I mentioned in my opening remarks, or we have procure the excuse me that's D.S. So on one off of order for stimulation broader.
Oh, we have not been suit as we can see from public events. So indeed, the preparing show the launch an approval of your beautiful impressed or Geneone I learned board for M.D.N.B.B., I and I'd write an appropriate time, you do though or disclose that grew up Bradley you're going to broader but I'd be very young or.
Moving their name of the product.
Should we think about this is a potential 2021 opportunity.
Ah yes.
Okay.
Thanks, gentlemen, I'll get back in line.
Thank you Greg.
Thank you.
The next question comes from Randall Stanicky from RBC. Please go ahead.
Great. Thanks, guys, Hey truck I wonderful up on the last question, you called out and Jones being one of the.
Largest U.S. generic manufacturers is it your view that any economic incentives from the government.
Could be limited to U.S. domain felt companies. So that's the that's the first question then process.
On the generic gross margin coming in at 42% can you get into some more detail on what you're expecting.
Around some of the the puts and takes that March this year, it sounds like you're still holding to that 40% target.
Now what are the factors that could push that generic gross margin higher thanks.
So to handle a good morning up do you estimate Saudi is where the largest you asked oversight company I don't believe yes that would be served in a incentives given too and this is all work in progress we're part of a dialogue.
But it's going to need obviously more than you were still inside the company that is going to need the companies that already have started and expertise.
And capability somewhere else to bring back production Boston Phase I to foster base other than its lower base and do that we need to hang tight industry to work together.
To make this happen.
I suppose.
Hey, right any Randall this is house was so a couple of things. So I see as you said Q1 generic adjusted gross margin was 42% and just to kind of put things in context, that's essentially flat to up same period last year and the.
Dynamic berries.
We had overall price pressures.
As you know they came in and a lot there part of last year, we had some of our key projects. We launched last year generic competition and be offset to that was the launch of our new products generic kind of faith and Mr. prophage.
Oh, so that that's 111.
Drive the second thing is in Q1 also we benefited for some favorable manufacturing.
The option so our manufacturing teams worked incredibly hard to keep up with the demand in that marketplace. So that kind of benefited us in in Q1, and they may be a slight offsetting in Q2. So that's more of a timing Q1 Q2, the generic gross margin, but that's kind of states stepping back for a second.
Is you know we feel great about the gross margins you know who are still targeting.
You know this year are making meaningful.
Progress a in terms of adjusted gross margin growth last year. As you know we were at 35 and a half or send this year, we're looking for a meaningful.
Increase towards that 40% plus and the key driver to not that it's twofold number one is our our ability to get you probably have to the market. So we feel good about that that's what seemed to talked about focus over the R&D to produce.
And get get approvals of hard to make.
Generic products. So we feel good about that that's going to be key driver.
Second key driver frankly is you know is you know, we're hoping to see lower price erosion and this year as what we had seen probably here. So these are competitive marketplace. A commercial teams are spending a lot of time bidding for new projects.
So that's going to be the second driver is the price erosion in the model in the marketplace. No. It's one man's opinion, that's my opinion, which says you know these cobiz 19 has food that premium on companies that I have a diversity by diversified supply chains and at some point in.
Hi that has to show up in the pricing of those products. So let me, let me stop here and hopefully that answered your question.
Yeah are you seeing your ability to take price in this current market has koby great team maybe brought back some of the pricing power the generic seem to have lost over the last couple of years.
So then I'll take that one so just wanted to recreate the gross margin or increase as you know we focused on increasing or the base business. Since August of last year that has no ramped up and will continue to do do that along with new launches in fourth quarter as well as.
First quarter.
Which we have a high utilizations at it it every plant the price increase.
It is not a busy the market is still a dead. We are facing price increases from already be I supplies and freight costs, but we're not able to pass those increases to a customer is wearing a dialogue with them.
And hopefully we will a little work.
To get they've done a day.
They.
The industry still is highly concentrated from the buying power so.
What we're not seeing is many challenges which is a good news.
And I couldn't be two reason ones is one is that already prices are way down it off more than prices. So there's no more.
I used to go down in most of the product. So many products and a second reason is that customers are now thinking about more about.
Securing the supply chain reliable partners. So we're seeing more a more partnership or to do that and that may improve the pricing environment Enginetics.
Got it thanks guys.
The next question comes from below sheep for Sard from Barclays. Please go ahead.
Hi, good morning, everyone. Thanks, transgressions distinct again, China. So a couple of questions on the genomic side.
Well firstly since you commented on the pricing erosion other long lead on from there Oh, So what kind of fed Ocean do you see on your existing brought a nice as it starts you don't see portions of the what you're seeing the last one or two years and I'm just I'm on the question that Randall just toss now or are you seeing any fundamental dynamics change between the bad simulation.
James and how should we think of days going forward lastly.
Can you also just I'll comment on the ammonium thought of competition launches into the guidance, especially into a new England cafes, and how we may impact the range provider. Thanks.
Hi, biology, good morning.
So let me take your first question or the price erosions as I said, we have seen or less than the prior years and we hope.
Or that we continue to see that trend because frankly, there is not.
Any room left or otherwise, we would have to discontinued products and.
The fundamental change you talked about is.
Is is happening I don't know is that which face it's going to go do but now.
Evaluating all the big customers on their supply chain, having more <unk>, having a partnering for longer terms. So we don't need to worry about losing a product with them in six months. So we can find properly.
So longer term contracts offering works as well.
More diversified so having a alternate sources oh PPI, having to alternate sources of finished products. So all those questions. I mean, you ask wet AMD new plays a deal.
With his trends and obviously the quality track record because we have multiple products with euro VI sources, you a manufacturing, India and U.S.. So we're able to two to winning business.
No more business, then maybe our competitors Oh, but I do believe that a certain long time, a fundamental changes are coming.
As we focus more on that securing the supply chain and and and partner with the reliable sources Youre a third question on the wording and a so called quite Oh, we had a solid first quarter and continue to build on it so called freight we already have.
Great market share them, almost 60% looting rebuild the capacity to get up to 30%, which will start doing that now.
We have with automated process approved by FDA and are already producing more products.
Thank you.
Next question comes from.
Ami Fadia from SVB near Nick Please go ahead.
Hi, Good morning, Thanks My question.
Oh, that's tubing manufacturing back to the U.S.
Can you talk about.
The can you haven't quantified in Cleveland.
He's manufacturing.
Thats, what do we brought to the U.S. and what's the appetite even in the government all kind of the key buyers that's got to do that increase Oh.
And with regard to just timeline you mentioned that buses.
Long term process.
But it isn't new positions to respond.
On certain products.
Crohns given its 50 manufacturing footprint.
And then separately you know what are your current a thought the got too.
Business developmental partnership and when would you prioritize that or would it be and especially side or generic [laughter] elaborate on that thank you.
Good morning, I mean, Oh so.
Back to the U.S. the manufacturing as I said, it is certain capabilities and capacity or needs to be built here and Congress is exploding radius bills or they may be putting that it's well as I said work in progress, putting some task force with National Academy.
So signs and coming up with essential product list, a as I said it well in wall, then Todd industry, and it's a pretty large undertaking but it is being considered seriously.
Again, it's in only process I don't know the timing of when they ask what are what input we put a wider would end up.
Oh and.
The cost analysis would have to be undertaken.
The.
Basic material or enrollment deal costs is shouldn't be the same but it's in Europe, China or.
Or U.S. is the cost of operating wouldn't be higher here.
And labor labor costs. So we haven't quantified that how many products, we need the list of essential products, which one amneal wouldn't be playing a role in it and it would be a combined to do processes of the free enterprise World Amneal would act fast because I'm Neal is it solely focused on U.S.
Market. So everything we do is always geared toward the United States market and we have Ah Ah strong manufacturing position on a finished dosage form.
And we are known photo execution.
This is how we build them Neil one point, though and doing it again in M. Neal 2.0, so we would like faster than or participate in a competitive process.
On the business development front.
The specialty remains on focus.
We would they were looking for a complementary assets to a movement disorder franchise as well as endocrinology, Oh I would have to be a could you do.
Not looking for again, I'm I said, it before or looking to hit still some singles and doubles and not going forward or a bigger transaction at this point or we already have.
So many assets that we can exit geared up on within our the R&D bolt on a genetics and specialty so ready yet ready focus that as well.
Thank you and me.
The next question comes from Elliot Wilbur from Raymond James. Please go ahead.
Thanks. Good morning, just wanted to ask a couple of questions around future pipeline opportunities and specifically thinking about potential disruption to ongoing review just wondering if youre seeing noticing any impact in terms of F.D.A. tie lines, particularly with respect to some of your higher barrier to entry.
Tree or complex generic products, certainly seems like the uptake continues to prove a lot of generics, but just wondering if.
You're seeing timelines, maybe slow for review of some of the more complicated products are considering issues such as inability conduct inspections and the like and then maybe just a an update on some pipeline projects that I talked about previously, but maybe haven't been mentioned the last couple calls and specifically thinking about generic versions of a co pack. So.
Restasis, whether or not you still see those is 2020 opportunities. Thanks.
[noise] chewed through your own earlier.
Yeah, Hi, good morning earlier.
Regarding your parts questions, we haven't already seen any delays or on our goal dates from after the game and you see that a it will be or companies that they pick it I mean I enjoy their pain, but the quality track record over about a 18 years and I think that goes long way and or rather the company.
So they get a broader <unk>.
In any shape do you know where gold age then there nude working really really good you get ideally what do think agent before doing all the work. They are doing in Q1 circumstances and situation. So we do you mean or Paul good people and our new launches for the remainder of the year.
Regarding your second question on Copaxone heavy stuff recently, we've kind of Oh in a regulatory limbo. So I'm not in a position do they want great in it that he guiding then bad industry and whatever they didn't comes out okay didn't they would be applicable to everybody sorry.
During her paying like import we've tested cut backs on either during peak R&D going launch for us.
The next question comes from David Amsellem from Piper Sandler. Please go ahead.
Thanks, So just expanding upon the a theme of pipeline you cited also a door resolve filing which I believe is off patent do you expect that that's going to be a limited competition and potentially a a near term launch.
That's I think an interesting and unique product given the challenges, but what are your thoughts on potential potential for that as an opportunity and then and then secondly in your in injectable pipeline beyond thinking beyond the pack. So what's your view on the extent.
What you want to further build out a hospital injectable franchise and from a a biz Dev four or internal development perspective, how big of a priority is a hospital injectables in the context severe of all business. Thanks.
Yeah, Hi, buried but that can do a good morning.
Regarding your dealers or a new goes only the ready complex brought it back there you don't see that much competition. There's many bad years, though pantry, you're tracking nicely me that did and we expect a or maybe late fourth quarter garden activity.
Hi, good front the one launch.
Oh, okay.
Regarding or what injectable pipeline as I mentioned, we had been bingo, what injectable portfolio and we are excited about Oh, our pipeline or we have a different areas within injected let's start on your working aggressively to be on certain people do complex vindictive willing if a French and drug device combination products.
Oh, many ophthalmic garden. So we are focused including certain why would probably be too. Good order you know what injectable pipeline there opened up many more hospital chains. So.
Looking at all that back same time, yet also expanding or manufacturing in Europe, and India or injectable pipeline.
We already have in about 30 to 40 product being pipeline, putting their care about book, where youre really going to be ready differentiated high and injectable product that will bring certain key value due to page and and doctors.
Thank you.
The next question comes from Gary Nachman from BMO capital markets. Please go ahead.
Thanks. Good morning, first can you quantify how much Kobe benefited and one Q how much stockpiling, there wasn't a quarter and how much could that reversed in the coming quarters smart color on that would be helpful.
And now that you you've owned that care for pretty much what are some of the opportunities you've identified for that business. How much could you potentially drive incremental volume for Amneal space business grew F. cares network. Thank you.
<unk>.
That's right.
I'll take the Cobra.
And.
[music].
Good good morning.
From a coping ninety's when it was no material impact to to Q1, we were very socially responsible and the way we managed our inventory to try to avoid stockpiling at at the at the commercial marketplace. So there was no material impact in Q1 Kobin 19.
Tussaud's, you may want to give more color on a.
Covert 19 impact.
Yeah, Yeah. So.
Just to reiterate what what what then be said, so while discount provide a little bit more color or some of the puts and takes so number. One is you know we do get the same hold wholesaler inventory data out in the trade.
And there was.
Nothing abnormal in terms of total company. So a week's on hand actually decline at the end of Q1 versus the end of the year, which is difficult because the end of the year. They typically or there are an extra week. So there was nothing abnormal they're not number one number.
Number two internally you know because because of the.
This discrepancy Asian D E book to that business, we had another of open positions that we did not feel however.
We had substantial more overtime in the manufactured in place. So there's substantial overtime in the manufacturing plans offset some operating expenses were ability and related to headcount related costs. We also had incremental substantial incremental cost regarding freight which I think every every company was impacted by that.
You know the final thing is we saw our R&D expenses were slightly favorable into Porter and that's because we couldn't get those my talk to material that we wanted for some of the trials.
And some of the project so well overall overall I would say the impact to the quarter was was not material and there was nothing in our heads that says that that will be reversing in Q2 [noise].
That's correct.
Got it thank you to us as it should get together.
Gary I just wanted to act that yes, that's a good question or the first quarter performance is solely is and news performances, what we've been doing since.
Last August is a.
It traded that increasing based business launching new products Hyatt efficiencies. All these hub and spoke performance by specialty with their marketing initiatives and have CAD, which adds an excellent or add on to N. Neal ready complementary.
Oh, Carafate is not being solely by.
Okay would carry afraid has it increased demand due to is you know the reflected in products and tech was rolled out of market and that has devoted more demand to kind of freight.
Hopefully that answers your question Gary.
Yes, and just a little more an app aren't going forward is there anything more you could do with that business to drive a more growth. Then you know what what are we seeing previously just how we should think about that trajectory for that business.
Yeah. So that is one of course strategic initiatives, along with growth in genetics and growth in specialty.
Good.
Oh, they're very well say didn't goldman or two to sell genetics product, but now they're looking it's.
Selling more topic or getting in the long term contracts with a biosimilar products and specialty products as well a and then that is other initiatives that BARDA.
As used up at stockpiled ore is concerned about or any future or current demand through the pandemic. So they're looking to stockpile.
More products as well so all these these opportunities for okay, and the Unidos businesses small at this point, but we are putting up a liquid infrastructure, which will then take the unit dose liquid business or by the growth will come by.
Probably next year and unit dose liquid business multiple avenues to grow at <unk>.
Okay. Thank you.
Thanks.
The next question comes from Chris Schott from JP Morgan. Please go ahead.
Great. Thanks, so much further questions on just two for me first you mentioned some share recapture on the base business is helping with generic results keeps elaborate a bit more in the trends you're seeing there and print more importantly, as we think about the or is there more opportunity going forward to further improve share on the existing portfolio and then.
My second question was one bio Similars and I think you referenced a desire to pursue licensing deals or partnership deals here, just a little bit more color. There should we think about these as nearer term product launches are longer term opportunities.
Interesting about the company targeting assets that have already completed clinical programs or conceptually could these deals resulting to step up in R&D spend so we think about the go forward business. Thanks, so much.
Good morning, Chris.
Your first question on base business. They trend continues as and Neil has a diversified supply chain and with Cowen 19 actually.
Customers are looking to diversify said, they're buying hundred percent up their products from India, or euro or or vice versa. They want to.
Diversify and if you're U.S. Mays manufacturing, they're looking to add a certain percentages of the business in U.S. as well. So trend is very positive as we have a very large portfolio up 250, plus products and keep launching new products. It very strong generic business and we.
But continue to win new businesses and our quality track record also comes in handy because of the reliability of wood products as well bio Similars, we have suite products in the pipeline.
We expect a launches 2021 22 for those products.
And we had it carefully adding products as we are learning more and more about the market and how it behaves its squads I call. It was I branded market. So you need a lot. So if I put so it focuses more on oncology, where where do we would do have started buildings.
Small infrastructure and and ER, we relied on to we already have a very nice specialty branded a infrastructure. So we'll leverage that as well without adding any further cost.
So our goal is to in licensed products, where we ought and this is 10 years view, we're always rebuilt company over a long time.
Oh that we would end licensed products, which were potentially we couldn't be.
First is going to be hard at this point, but let's say second third fourth we do not want to me.
After that so because it becomes ready a compared it to be on fourth player. So that is what we're looking to build on call you pipeline going forward or any other interesting IP doing it puts you stick pipe line as well.
Thank you Chris.
Okay.
It's clean slate.
I'm sorry. This concludes our question and answer session I would like to turn the conference back over to toss. This kinda doors for any closing remarks.
Oh really what I think a number one our team for doing an incredible job in Q1, staying focused on the business for the rest of the year and I really want to thing our investors for being with us and our customers that rely on our products and services.
Thank you and have a great night away.
Thank you.
Thank you.
The conference has now concluded thank for attending today's presentation you may now disconnect.
[music].